BE1003188A4 - Composition pharmaceutique destinee a etre administree par voie orale et contenant de la n-acetyl-cysteine, et son application. - Google Patents

Composition pharmaceutique destinee a etre administree par voie orale et contenant de la n-acetyl-cysteine, et son application. Download PDF

Info

Publication number
BE1003188A4
BE1003188A4 BE9000746A BE9000746A BE1003188A4 BE 1003188 A4 BE1003188 A4 BE 1003188A4 BE 9000746 A BE9000746 A BE 9000746A BE 9000746 A BE9000746 A BE 9000746A BE 1003188 A4 BE1003188 A4 BE 1003188A4
Authority
BE
Belgium
Prior art keywords
cysteine
acetyl
oral administration
pharmaceutical composition
application
Prior art date
Application number
BE9000746A
Other languages
English (en)
Inventor
Angelo Carenzi
Dario Chiarino
Antonio Longo
Original Assignee
Zambon Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zambon Spa filed Critical Zambon Spa
Application granted granted Critical
Publication of BE1003188A4 publication Critical patent/BE1003188A4/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches

Abstract

Cette composition pharmaceutique contient de la N-acetyl-cystéine et du trihydroxyméthyl-aminométhane dans un rapport molaire compris entre 1:0,8 et 1:1,2. Cette composition permet d'obtenir, par administration orale, une augmentation significative de la quantité de N-acetyl-cystéine non modifiée dans le flux sanguin, en comparaison des teneurs que l'on peut obtenir par administration orale de composition contenant de la N-acétyl-cystéine telle quelle ou sous forme d'un sel.
BE9000746A 1989-07-27 1990-07-26 Composition pharmaceutique destinee a etre administree par voie orale et contenant de la n-acetyl-cysteine, et son application. BE1003188A4 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT8921339A IT1231012B (it) 1989-07-27 1989-07-27 Composizione farmaceutica per uso orale contenente nac.

Publications (1)

Publication Number Publication Date
BE1003188A4 true BE1003188A4 (fr) 1992-01-07

Family

ID=11180335

Family Applications (1)

Application Number Title Priority Date Filing Date
BE9000746A BE1003188A4 (fr) 1989-07-27 1990-07-26 Composition pharmaceutique destinee a etre administree par voie orale et contenant de la n-acetyl-cysteine, et son application.

Country Status (20)

Country Link
US (1) US5080906A (fr)
JP (1) JPH0399012A (fr)
KR (1) KR910002438A (fr)
AU (1) AU625925B2 (fr)
BE (1) BE1003188A4 (fr)
CA (1) CA2021808A1 (fr)
CH (1) CH680190A5 (fr)
DE (1) DE4023774A1 (fr)
DK (1) DK177890A (fr)
FI (1) FI903759A0 (fr)
FR (1) FR2650503B1 (fr)
GB (1) GB2234171B (fr)
GR (1) GR900100569A (fr)
IE (1) IE902627A1 (fr)
IL (1) IL95158A0 (fr)
IT (1) IT1231012B (fr)
NL (1) NL9001714A (fr)
NZ (1) NZ234647A (fr)
SE (1) SE9002500L (fr)
ZA (1) ZA905861B (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5580577A (en) * 1990-01-11 1996-12-03 Herzenberg; Leonard A. Method of treating the symptoms of human rhinovirus infection
US5286480A (en) * 1992-06-29 1994-02-15 The Procter & Gamble Company Use of N-acetylated amino acid complexes in oral care compositions
IT1256616B (it) * 1992-12-02 1995-12-12 Zambon Spa Sciroppo contenente n-acetil-cisteina
GB9226729D0 (en) * 1992-12-22 1993-02-17 Wellcome Found Therapeutic combination
US5637616A (en) * 1993-06-18 1997-06-10 Arcturus Pharmaceutical Corporation Method for treating diseases mediated by proteases
BE1007926A3 (fr) * 1994-01-31 1995-11-21 Zambon Int Pharma Composition pharmaceutique contenant de la n-acetyl-cysteine.
US6896899B2 (en) * 1996-12-31 2005-05-24 Antioxidant Pharmaceuticals Corp. Pharmaceutical preparations of glutathione and methods of administration thereof
WO1998029101A1 (fr) 1996-12-31 1998-07-09 Antioxidant Pharmaceuticals Corporation Preparations pharmaceutiques de glutathion et modes d'administration de ces preparations
FR2803720B1 (fr) * 2000-01-18 2004-10-22 Roquette Freres Lozenges a base de dextrose et leur procede de fabrication
US6114387A (en) * 2000-02-16 2000-09-05 Cutler; Paul Pharmaceutical composition for oral administration of chelating agents
US6632459B2 (en) * 2000-12-11 2003-10-14 Nutricia N.V. Chlorogenic acid and an analog thereof for immune system stimulation
US20030162732A1 (en) * 2001-07-05 2003-08-28 Astion Development A/S Combination of aminosugars and cysteine or cysteine derivatives
US20090035260A1 (en) * 2002-07-29 2009-02-05 Therapicon Srl Enhanced nasal composition of active peptide
ITMI20021881A1 (it) * 2002-09-04 2004-03-05 Zambon Spa Composizioni farmaceutiche per il trattamento di infezioni da patogeni dell'apparato urinario.
US20050008699A1 (en) * 2003-07-11 2005-01-13 Fred Wehling Effervescent glucosamine composition
ITMI20040235A1 (it) * 2004-02-13 2004-05-13 Therapicon Srl Preparazione farmaceutica per il cavo orale
KR20050104152A (ko) * 2004-04-28 2005-11-02 최승호 경구용 약물의 흡수를 증진하는 약제학적 조성물
US20090197956A1 (en) * 2008-02-04 2009-08-06 Arbor Pharmaceuticals, Inc. Treatment of acute otitis media with xylitol and n-acetylcysteine
TR200900882A2 (tr) 2009-02-05 2010-08-23 Bi̇lgi̇ç Mahmut Tadı ve kokusu maskelenmiş, bıyoyararlanımı yüksek farmasotık bileşimler.
LT3554491T (lt) * 2016-12-15 2023-05-25 Zambon S.P.A. N-acetilcisteinas, skirtas naudoti kaip antibakterinis agentas
DK3829535T3 (da) * 2018-07-27 2024-02-05 Icf Srl Sammensætninger til forebyggelse og behandling af kutane lidelser

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2192790A (en) * 1986-07-24 1988-01-27 Inpharzam Int Sa Acetylcysteine compositions
EP0339508A1 (fr) * 1988-04-29 1989-11-02 Altergon S.A. Compositions pharmaceutiques solubles dans la bouche contenant de l'acétylcystéine

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4081534A (en) * 1973-09-11 1978-03-28 Burroughs Wellcome Co. Amino purine nucleosides as autoimmune suppressant agents
US4877612A (en) * 1985-05-20 1989-10-31 Frank M. Berger Immunological adjuvant and process for preparing the same, pharmaceutical compositions, and process
US4894225A (en) * 1987-03-02 1990-01-16 Cetus Corporation Combination therapy using antitumor immunotoxins with tumor necrosis factor
JPS63290824A (ja) * 1987-05-22 1988-11-28 Sumitomo Chem Co Ltd ウイルス感染症治療剤

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2192790A (en) * 1986-07-24 1988-01-27 Inpharzam Int Sa Acetylcysteine compositions
EP0339508A1 (fr) * 1988-04-29 1989-11-02 Altergon S.A. Compositions pharmaceutiques solubles dans la bouche contenant de l'acétylcystéine

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BIOLOGICAL ABSTRACTS, vol. 83, no. 1, 1987, résumé no. 7424, Biological Abstracts, Inc., Philadelphia, PA, US; N. SALTZMAN et al.: "Chemolysis of cystine calculi", & J. UROL. 136(4): 846-849. 1986 *
BIOLOGICAL ABSTRACTS, vol. 83, no. 1, 1987, résumé no. 7425, Biological Abstracts, Inc., Philadelphia, PA, US; J.R. BURNS et al.: "In vitro dissolution of cystine urinary calculi", & J. UROL. 136(4): 850-852. 1986 *

Also Published As

Publication number Publication date
FR2650503A1 (fr) 1991-02-08
DK177890D0 (da) 1990-07-26
CA2021808A1 (fr) 1991-01-28
GB2234171B (en) 1993-11-10
AU5993590A (en) 1991-01-31
NL9001714A (nl) 1991-02-18
DE4023774A1 (de) 1991-01-31
IE902627A1 (en) 1991-02-27
KR910002438A (ko) 1991-02-25
AU625925B2 (en) 1992-07-16
IT1231012B (it) 1991-11-08
GR900100569A (el) 1991-12-10
SE9002500D0 (sv) 1990-07-26
IL95158A0 (en) 1991-06-10
FR2650503B1 (fr) 1992-05-29
ZA905861B (en) 1991-07-31
GB2234171A (en) 1991-01-30
NZ234647A (en) 1992-02-25
SE9002500L (sv) 1991-01-28
DK177890A (da) 1991-01-28
CH680190A5 (fr) 1992-07-15
GB9016256D0 (en) 1990-09-12
IT8921339A0 (it) 1989-07-27
JPH0399012A (ja) 1991-04-24
US5080906A (en) 1992-01-14
FI903759A0 (fi) 1990-07-27

Similar Documents

Publication Publication Date Title
BE1003188A4 (fr) Composition pharmaceutique destinee a etre administree par voie orale et contenant de la n-acetyl-cysteine, et son application.
TNSN01166A1 (fr) Composes agonistes selectifs des recepteurs ep4 et compositions les contenant.
TNSN98182A1 (fr) Agonistes de prostaglandines nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
ATE26705T1 (de) 1-carboxyalkanoylindolin-2-carbonsaeuren und deren derivate, verfahren zu ihrer herstellung, und pharmazeutische praeparate, die diese verbindungen enthalten.
KR830001649A (ko) 생체조직 및 혈액과 화합(和合)할 수 있는 물질
TNSN98236A1 (fr) Derives d'erythromycine nouveaux, procede et intermediaires pour leur preparation, et compositions pharmaceutiques les contenant
FR2432536A1 (fr) Emulsion de silicone pour le traitement de matieres particulaires a base de silicate
TNSN99170A1 (fr) Derives de tetrahydroquinoleine substitues nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
FR2442054A1 (fr) Proteines purifiees, notamment interferon, procede de preparation et compositions pharmaceutiques les contenant
KR890009383A (ko) 지방산 합성물
TNSN97208A1 (fr) Prevention de la perte et restauration de la masse osseuse par certains agonistes des prostaglandines
NO20003698L (no) Orale sammensetninger
FI880629A (fi) Fosfopeptidejä, niiden valmistusmenetelmä ja käyttö sekä niitä sisältäviä suunhuoltokoostumuksia
TNSN98238A1 (fr) Macrolides nouveaux
TNSN01046A1 (fr) Ethers de diphenyle utiles en therapeutique
Florkin Nitrogen metabolism
BE900563A (fr) Composition pharmaceutique pour le traitement d'etats d'insuffisance renale aigue.
EP0069678A3 (fr) Dérivés de 3-fucosyl-N-acétyl lactosamine, leur préparation et leurs applications biologiques
FR2450605A1 (fr) Composition pour traiter la cavite orale et procede de preparation
Reed et al. Potassium-dependent stimulation of respiration in brown fat cells by fatty acids and lipolytic agents
FR2385506A1 (fr) Procede de traitement du bois par un agent de preservation du bois et bois traite par ledit agent de preservation du bois
HUP0202243A2 (hu) Ketotiféntartalmú szemészeti készítmény
BR0011928A (pt) Composto, composição farmacêutica, uso de, um composto e métodos para o tratamento de complicações diabéticas, para o tratamento ou a prevenção do desenvolvimento de condições de doença associadas com velocidade de condução neuronial prejudicada e de neuropatia diabética
TNSN86004A1 (fr) Compose pharmaceutiquement actif et procede pour sa preparation
TNSN01115A1 (fr) Composition en particules contenant de l'eletriptan, et procede pour sa production

Legal Events

Date Code Title Description
RE Patent lapsed

Owner name: ZAMBON GROUP S.P.A.

Effective date: 19940731